<i>Fusobacterium nucleatum</i>in colorectal carcinoma tissue and patient prognosis
2015/08/26 by Kosuke Mima, Reiko Nishihara, Zhi Rong Qian +33 · 35 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Agricultural and Biological Sciences · #Gut microbiota and health #Otolaryngology and Infectious Diseases #Probiotics and Fermented Foods
paper · doi:10.1136/gutjnl-2015-310101
Abstract
OBJECTIVE: Accumulating evidence links the intestinal microbiota and colorectal carcinogenesis. Fusobacterium nucleatum may promote colorectal tumour growth and inhibit T cell-mediated immune responses against colorectal tumours. Thus, we hypothesised that the amount of F. nucleatum in colorectal carcinoma might be associated with worse clinical outcome. DESIGN: We used molecular pathological epidemiology database of 1069 rectal and colon cancer cases in the Nurses' Health Study and the Health Professionals Follow-up Study, and measured F. nucleatum DNA in carcinoma tissue. Cox proportional hazards model was used to compute hazard ratio (HR), controlling for potential confounders, including microsatellite instability (MSI, mismatch repair deficiency), CpG island methylator phenotype (CIMP), KRAS, BRAF, and PIK3CA mutations, and LINE-1 hypomethylation (low-level methylation). RESULTS: Compared with F. nucleatum-negative cases, multivariable HRs (95% CI) for colorectal cancer-specific mortality in F. nucleatum-low cases and F. nucleatum-high cases were 1.25 (0.82 to 1.92) and 1.58 (1.04 to 2.39), respectively, (p for trend=0.020). The amount of F. nucleatum was associated with MSI-high (multivariable odd ratio (OR), 5.22; 95% CI 2.86 to 9.55) independent of CIMP and BRAF mutation status, whereas CIMP and BRAF mutation were associated with F. nucleatum only in univariate analyses (p<0.001) but not in multivariate analysis that adjusted for MSI status. CONCLUSIONS: The amount of F. nucleatum DNA in colorectal cancer tissue is associated with shorter survival, and may potentially serve as a prognostic biomarker. Our data may have implications in developing cancer prevention and treatment strategies through targeting GI microflora by diet, probiotics and antibiotics.
Cited by
- Quantitation of faecal <i>Fusobacterium</i> improves faecal immunochemical test in detecting advanced colorectal neoplasia
- Cancer invasion and anaerobic bacteria: new insights into mechanisms
- An Empirical Dietary Pattern Associated With the Gut Microbial Features in Relation to Colorectal Cancer Risk
- Characterization of the gut microbiome in epidemiologic studies: the multiethnic cohort experience
- Emerging role of bacterial extracellular vesicles in cancer
- <i>Fusobacterium</i>’s link to colorectal neoplasia sequenced: A systematic review and future insights
- Exploring the Key Role of Nanotechnology on Intratumoral Microbiome Modulation for Cancer Immunotherapy
- Microbial Metabolites and Gut Immunology
- Colon Cancer-Associated Fusobacterium nucleatum May Originate From the Oral Cavity and Reach Colon Tumors via the Circulatory System
- Gastrointestinal cancer: molecular pathogenesis and targeted therapy
- Taurocholic acid metabolism by gut microbes and colon cancer. [europepmc]
- The Gut Microbiota in Immune-Mediated Inflammatory Diseases. [europepmc]
- Gut Microbiota, Inflammation, and Colorectal Cancer. [europepmc]
- Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21. [europepmc]
- Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue. [europepmc]
- Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. [europepmc]
- Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. [europepmc]
- Human Gut Microbiota and Gastrointestinal Cancer. [europepmc]
- Environmental Factors, Gut Microbiota, and Colorectal Cancer Prevention. [europepmc]
- Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis. [europepmc]
- Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. [europepmc]
- Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. [europepmc]
- Modulating the microbiome to improve therapeutic response in cancer. [europepmc]
- Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. [europepmc]
- Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. [europepmc]
- Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. [europepmc]
- Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. [europepmc]
- Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. [europepmc]
- The role of gut microbiota in cancer treatment: friend or foe? [europepmc]
- Rising incidence of early-onset colorectal cancer - a call to action. [europepmc]
- Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. [europepmc]
- The Intestinal Microbiota and Colorectal Cancer. [europepmc]
- Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? [europepmc]
- A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. [europepmc]
- A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. [europepmc]
Related